Benitec Biopharma Ltd
ABN 64 068 943 662

F6A / 1-15 Barr Street Balmain NSW 2041 Australia

> Tel: +61 (0) 2 9555 6986 Email: info@benitec.com

> > www.benitec.com

ASX ANNOUNCEMENT

RESULTS OF THE GENERAL MEETING HELD ON WEDNESDAY 17 JULY 2013

Sydney, Australia, 17 July 2013, In accordance with Listing Rule 3.13.2 and section 251AA of the Corporations Act, we advise details of the resolutions and the proxies received in respect of each resolution on the agenda of this morning's Annual General Meeting.

Resolution 1, Consolidation Of Shares And Existing Options And Warrants

The instructions given to validly appointed proxies in respect of the resolution were as follows:

For	Against	Abstain	Proxy's discretion
79,221,065	7,384,325	39,220	248,689,684

The motion was carried as an ordinary resolution on a show of hands.

Resolution 2, Adoption Of New Constitution

The instructions given to validly appointed proxies in respect of the resolution were as follows:

For	Against	Abstain	Proxy's discretion
83,610,696	2,922,361	114,220	248,689,684

The motion was carried as a special resolution on a show of hands.

Resolution 3, Ratification Of Prior Issue Of Placement Securities

The instructions given to validly appointed proxies in respect of the resolution were as follows:

For	Against	Abstain	Proxy's discretion
68,020,752	3,241,909	0	240,997,376

The motion was carried as an ordinary resolution on a show of hands.

Resolution 4, Ratification Of Prior Issue Of Placement Securities

The instructions given to validly appointed proxies in respect of the resolution were as follows:

For	Against	Abstain	Proxy's discretion
82,079,498	4,256,547	0	248,689,684

The motion was carried as an ordinary resolution on a show of hands.



Resolution 5, Approval For Director Participation In Placement – Mr Peter Francis

The instructions given to validly appointed proxies in respect of the resolution were as follows:

For	Against	Abstain	Proxy's discretion
80,928,712	5,598,562	120,003	248,689,684

The motion was carried as an ordinary resolution on a show of hands.

Resolution 6, Approval For Director Participation In Placement – Dr Melvyn Bridges

The instructions given to validly appointed proxies in respect of the resolution were as follows:

For	Against	Abstain	Proxy's discretion
79,477,227	7,050,047	120,003	248,689,684

The motion was carried as an ordinary resolution on a show of hands.

Resolution 7, Approval For Director Participation In Placement – Dr John Chiplin

The instructions given to validly appointed proxies in respect of the resolution were as follows:

For	Against	Abstain	Proxy's discretion
79,449,391	7,016,047	154,003	248,689,684

The motion was carried as an ordinary resolution on a show of hands.

Resolution 8, Approval For Issue Of Placement Securities

The instructions given to validly appointed proxies in respect of the resolution were as follows:

For	Against	Abstain	Proxy's discretion
80,805,770	5,684,668	129,003	248,689,684

The motion was carried as an ordinary resolution on a show of hands.

Resolution 9, Approval For Director Participation In Placement – Mr Peter Francis

The instructions given to validly appointed proxies in respect of the resolution were as follows:

For	Against	Abstain	Proxy's discretion
79,333,542	7,056,896	229,003	248,689,684

The motion was carried as an ordinary resolution on a show of hands.



Resolution 10, Approval For Director Participation In Placement – Dr Melvyn Bridges

The instructions given to validly appointed proxies in respect of the resolution were as follows:

For	Against	Abstain	Proxy's discretion
79,336,209	7,054,229	229,003	248,689,684

The motion was carried as an ordinary resolution on a show of hands.

Resolution 11, Approval For Director Participation In Placement – Mr Iain Ross

The instructions given to validly appointed proxies in respect of the resolution were as follows:

For	Against	Abstain	Proxy's discretion
79,333,542	7,056,896	229,003	248,689,684

The motion was carried as an ordinary resolution on a show of hands.

For more information please contact:

Dr Peter French | Chief Executive Officer

Phone: +61 (02) 9555 6986 | pfrench@benitec.com | www.benitec.com

About Benitec Biopharma Limited:

Benitec Biopharma Limited is an ASX-listed biotechnology company (ASX:BLT) based in Sydney, Australia. The company has a pipeline of in-house and partnered therapeutic programs based on its patented gene-silencing technology, ddRNAi, also called expressed RNAi. Benitec Biopharma is developing treatments for chronic and life-threatening human conditions such as cancer-associated pain, Hepatitis B, Hepatitis C, drug resistant lung cancer and oculopharyngeal muscular dystrophy based on this technology. In addition, Benitec Biopharma has licensed ddRNAi technology to other biopharmaceutical companies for applications including HIV/AIDS and retinitis pigmentosa. For more information on Benitec Biopharma refer to the Company's website at www.benitec.com.